These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 32065106)

  • 1. Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019).
    He X; Li Z; Zhuo XT; Hui Z; Xie T; Ye XY
    Recent Pat Anticancer Drug Discov; 2020; 15(1):32-48. PubMed ID: 32065106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019).
    Shen S; Kozikowski AP
    Expert Opin Ther Pat; 2020 Feb; 30(2):121-136. PubMed ID: 31865813
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors.
    Liang YY; Zhang CM; Liu ZP
    Expert Opin Ther Pat; 2018 Aug; 28(8):647-651. PubMed ID: 30073889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).
    Simões-Pires CA; Bertrand P; Cuendet M
    Expert Opin Ther Pat; 2017 Mar; 27(3):229-236. PubMed ID: 28092474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragment-Based Drug Design of Selective HDAC6 Inhibitors.
    Ruzic D; Djokovic N; Nikolic K
    Methods Mol Biol; 2021; 2266():155-170. PubMed ID: 33759126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
    Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
    Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure, Functions and Selective Inhibitors of HDAC6.
    Liang T; Fang H
    Curr Top Med Chem; 2018; 18(28):2429-2447. PubMed ID: 30499393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the discovery of potent and selective HDAC6 inhibitors.
    Wang XX; Wan RZ; Liu ZP
    Eur J Med Chem; 2018 Jan; 143():1406-1418. PubMed ID: 29133060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.
    Tavares MT; Kozikowski AP; Shen S
    Eur J Med Chem; 2021 Jan; 209():112887. PubMed ID: 33035922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Novel Histone Deacetylase 6-Selective Inhibitors Bearing 3,3,3-Trifluorolactic Amide (TFLAM) Motif as a Zinc Binding Group.
    Kurohara T; Tanaka K; Takahashi D; Ueda S; Yamashita Y; Takada Y; Takeshima H; Yu S; Itoh Y; Hase K; Suzuki T
    Chembiochem; 2021 Nov; 22(22):3158-3163. PubMed ID: 34224197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
    Wu H; Yang K; Zhang Z; Leisten ED; Li Z; Xie H; Liu J; Smith KA; Novakova Z; Barinka C; Tang W
    J Med Chem; 2019 Aug; 62(15):7042-7057. PubMed ID: 31271281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
    Zhang XH; Qin-Ma ; Wu HP; Khamis MY; Li YH; Ma LY; Liu HM
    J Med Chem; 2021 Feb; 64(3):1362-1391. PubMed ID: 33523672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of histone deacetylase 6 based on a novel 3-hydroxy-isoxazole zinc binding group.
    Linciano P; Pinzi L; Belluti S; Chianese U; Benedetti R; Moi D; Altucci L; Franchini S; Imbriano C; Sorbi C; Rastelli G
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2080-2086. PubMed ID: 34583596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.
    Cosenza M; Pozzi S
    Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30096875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
    Nam G; Jung JM; Park HJ; Baek SY; Baek KS; Mok HY; Kim DE; Jung YH
    Bioorg Med Chem; 2019 Aug; 27(15):3408-3420. PubMed ID: 31235266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of High-Content Analysis for Screening HDAC6-Selective Inhibitors.
    Nong Y; Hou Y; Pu Y; Li S; Lan Y
    SLAS Discov; 2021 Jun; 26(5):628-641. PubMed ID: 33783263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics.
    Zhang Y; Ying JB; Hong JJ; Li FC; Fu TT; Yang FY; Zheng GX; Yao XJ; Lou Y; Qiu Y; Xue WW; Zhu F
    ACS Chem Neurosci; 2019 May; 10(5):2467-2480. PubMed ID: 30784262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
    Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K
    Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selectivity of Hydroxamate- and Difluoromethyloxadiazole-Based Inhibitors of Histone Deacetylase 6 In Vitro and in Cells.
    Ptacek J; Snajdr I; Schimer J; Kutil Z; Mikesova J; Baranova P; Havlinova B; Tueckmantel W; Majer P; Kozikowski A; Barinka C
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.